Vaxcyte, Inc. (PCVX)

Vaxcyte's stock has experienced significant fluctuations in the past six months, with a 35.47% increase despite a 60.49% decrease over the past year. In March 2025, positive topline results from the Phase 2 dose-finding study for VAX-24 in healthy infants were announced. In April 2025, the stock plummeted 56%, and Cantor Fitzgerald initiated coverage with an "Overweight" recommendation. In May 2025, Dr. Olivier Brandicourt was appointed to the Board of Directors, and the company reported a net loss of $140.7 million for Q1 2025. In June 2025, Vaxcyte was a "near-miss" for inclusion in the Russell 3000E Value Index and reported a net loss of $166.6 million for Q2 2025. In August 2025, Vaxcyte's Q2 loss widened by 11%, and the development of VAX-PG was discontinued. In September 2025, Goldman Sachs initiated coverage with a "Neutral" rating and a $38.00 price target, and Vaxcyte presented at healthcare conferences.

Specific demand seasonality for Vaxcyte, Inc.'s products and services is not explicitly detailed. As a clinical-stage vaccine company, its current revenue is from collaborations and milestones, not commercial product sales, which are not typically subject to seasonal demand. However, vaccines for infectious diseases like pneumococcal disease could imply potential future seasonality in demand once products are commercialized. Historical bias for PCVX stock leans short for October, with a statistically strong window culminating around November 13, 2025, suggesting some stock seasonality.

Vaxcyte, Inc. is a clinical-stage biotechnology company focused on developing innovative vaccines for serious bacterial infectious diseases, operating within the healthcare sector. They utilize Sutro Biopharma's Xpress CF Platform to create complex conjugate and protein-based vaccines. Their lead candidate is VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) for preventing invasive pneumococcal disease (IPD) in infants. The pipeline includes VAX-31, a 31-valent PCV for IPD in adults and children, and VAX-A1, a conjugate vaccine candidate for Group A Streptococcus. VAX-PG, a preclinical vaccine candidate targeting periodontitis, was discontinued due to insufficient efficacy signals. VAX-GI is another preclinical candidate for dysentery and shigellosis. As a clinical-stage company, Vaxcyte's financial performance depends on pipeline progress, collaboration agreements, licensing, and milestone payments.

Vaxcyte, Inc. is headquartered in San Carlos, California, United States. The company aims to address global health needs and target global markets for its vaccine candidates.

Vaxcyte's brand reputation is tied to its vaccine development progress and financial performance. Positive results from the VAX-24 infant Phase 2 study positively impacted its scientific reputation. The stock plummet, widening net losses, and discontinuation of VAX-PG negatively affected investor confidence. Analysts generally maintain a "Strong Buy" consensus rating, indicating a positive outlook on its product candidates and long-term growth potential.

Institutional shareholders own 96.78% of Vaxcyte, Inc., while insider shareholders hold 3.10%.